JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bakheit, A M O
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bakheit, A M O
Journal of Neurology Neurosurgery and Psychiatry 2004;75:665-666
© 2004 BMJ Publishing Group Ltd


EDITORIAL

Botulinum toxin treatment

Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity

A M O Bakheit

Correspondence to:
Correspondence to:
Professor A M O Bakheit
Neurological Rehabilitation, Peninsula Medical School and Plymouth Primary Care Trust, Mount Gould Hospital, Plymouth PL4 7QD, UK; magid.bakheit{at}pcs-tr.swest.nhs.uk


The correct research design is crucial in establishing whether treatments for complex neurological disorders are effective

Keywords: botulinum toxin; muscle spasticity; stroke

The first 150 words of the full text of this article appear below.

The effectiveness of botulinum toxin type A (BtxA) in reducing post-stroke muscle hypertonia and its complications has been demonstrated in adult patients in at least eight large randomised controlled trials (RCTs).1–8 The clinical benefits were reported when diverse treatment protocols and different dose schedules and injection techniques were used for the management of the same clinical indication. Nonetheless, some doubt as to the value of this treatment remain.9 What is the explanation for this apparent paradox? The contradiction may be explained by the inadequate design of these studies and the inherent difficulties with the interpretation of the results of RCTs of a drug treatment that is carried out in the context of rehabilitation for a person with chronic neurological disability. The WHO classification of functioning, disability, and health10 provides a useful framework for understanding the complex relation between the statistical significance and the clinical significance of a . . . [Full text of this article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd.